Six Upcoming Presentations at the Annual Meetings of the American Society of Gene and Cell Therapy (ASGCT) and of the...
Presented positive INB-100 data showing long-term complete remissions (CR) and elevated gamma-delta T cell levels in 100% of evaluable treated...
-- New long-term survival data disclosed from ELPIS I trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome; Data reinforce potential...
CHERRY HILL, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is a...
Successfully completed GLP toxicology studies for lead program GT-02287 in GBA1 Parkinson’s diseaseCompany is on track to submit application for...
CTA authorization provides approval for the Company to expand its planned CHORD™ Phase 1/2 clinical trial of DB-OTO to patients...
AUSTIN, Texas, May 12, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted...
– Continued to enroll patients in VIRAGE, the Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy...
Completed enrollment of the pivotal STRIDE study; topline results anticipated 4Q 2023Raised $68.3 million in gross proceeds from a concurrent...
Evo sEEG electrodes used for brain mapping in epilepsy surgery EDEN PRAIRIE, Minn., May 10, 2023 (GLOBE NEWSWIRE) -- NeuroOne...
Funds raised from Sterling Partners will be used to further innovative research and expand access to cutting-edge careCHICAGO, May 09,...
BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel...
Vaxxinity corporate headquarters in Cape Canaveral, Fla. Vaxxinity corporate headquarters in Cape Canaveral, Fla. (Photo: Vaxxinity)CAPE CANAVERAL, Fla., May 09,...
Lead-in data from Phase 3 PEAK trial to be presented at the American Society of Clinical Oncology (ASCO) 2023 Annual...
On track to provide clinical update from dose-escalation portion of Phase 1 clinical trial of EGFR MasterKey inhibitor BDTX-1535 in...
Trivehexin radiopharmaceuticals being developed for imaging and treatment of cancers expressing αvβ6-integrinPancreatic ductal adenocarcinoma is primary indication due to high...
SIG-002, Sigilon’s lead program for the treatment of diabetes, transitioning to IND-enabling and NHP studies in the second half of...
TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 08, 2023 (GLOBE NEWSWIRE) -- In preclinical studies, PMN310 demonstrated the ability to selectively...
BOSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous...
New HOLO AI Insights application aims to advance research of neuroanatomy utilizing artificial intelligenceDEERFIELD, Ill., May 08, 2023 (GLOBE NEWSWIRE)...